Combined treatment of pancreatic cancer xenograft with 90Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor.

about

Combined treatment of pancreatic cancer xenograft with 90Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor.

Item

http://www.wikidata.org/entity/Q45840119

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Combined treatment of pancreat ...... erapy and PI3K/mTOR inhibitor.

@en

Combined treatment of pancreat ...... erapy and PI3K/mTOR inhibitor.

@nl

type

Item

label

Combined treatment of pancreat ...... erapy and PI3K/mTOR inhibitor.

@en

Combined treatment of pancreat ...... erapy and PI3K/mTOR inhibitor.

@nl

prefLabel

Combined treatment of pancreat ...... erapy and PI3K/mTOR inhibitor.

@en

Combined treatment of pancreat ...... erapy and PI3K/mTOR inhibitor.

@nl

P1476

Combined treatment of pancreat ...... erapy and PI3K/mTOR inhibitor.

@en

P2093

Aya Sugyo

http://www.w3.org/2001/XMLSchema#string

Hitomi Sudo

http://www.w3.org/2001/XMLSchema#string

Katsushi Kouda

http://www.w3.org/2001/XMLSchema#string

Takako Furukawa

http://www.w3.org/2001/XMLSchema#string

Tatsuya Higashi

http://www.w3.org/2001/XMLSchema#string

Tsuneo Saga

http://www.w3.org/2001/XMLSchema#string

Winn Aung

http://www.w3.org/2001/XMLSchema#string

Yoshikazu Kurosawa

http://www.w3.org/2001/XMLSchema#string

P2860

The PI3K pathway as drug target in human cancer

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

The Ki-67 protein: from the known and the unknown

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.

Translation control: connecting mitogens and the ribosome.

Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.

Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.

The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses.

4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors.

P304

7551-7562

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V23.I42.7551

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Atsushi B Tsuji

Yoshinori Ukai

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29204055

http://www.w3.org/2001/XMLSchema#string

P921

xenograft

P932

5698248

http://www.w3.org/2001/XMLSchema#string